← Back to Screener
Lexicon Pharmaceuticals, Inc. (LXRX)
Price$2.07
Value ScoreD
Growth ScoreA
Momentum ScoreA
Favorite Metrics
Price vs S&P 500 (26W)49.22%
Price vs S&P 500 (4W)28.77%
VGM Score65.64
Market Capitalization$968.35M
All Metrics
Book Value / Share (Quarterly)$0.48
P/TBV (Annual)3.09x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)692.66%
Cash Flow / Share (Quarterly)$-0.09
Price vs S&P 500 (YTD)78.63%
Gross Margin (TTM)99.49%
Net Profit Margin (TTM)-37.46%
EPS (TTM)$-0.07
10-Day Avg Trading Volume1.95M
EPS Excl Extra (TTM)$-0.07
Revenue Growth (5Y)15.72%
EPS (Annual)$-0.14
ROI (Annual)-31.16%
Gross Margin (Annual)99.45%
Net Profit Margin (5Y Avg)-29324.68%
Cash / Share (Quarterly)$0.40
Revenue Growth QoQ (YoY)1572.11%
ROA (Last FY)-27.21%
Revenue Growth TTM (YoY)123.12%
EBITD / Share (TTM)$-0.06
ROE (5Y Avg)-107.73%
Operating Margin (TTM)-34.79%
Cash Flow / Share (Annual)$-0.19
P/B Ratio4.77x
P/B Ratio (Quarterly)3.26x
Net Income / Employee (Annual)$-621,500
EV / Revenue (TTM)14.07x
Net Interest Coverage (TTM)-5.04x
ROA (TTM)-11.79%
EV / EBITDA (TTM)23.00x
EPS Incl Extra (Annual)$-0.14
Current Ratio (Annual)4.88x
Quick Ratio (Quarterly)18.43x
3-Month Avg Trading Volume2.92M
52-Week Price Return230.40%
Revenue / Employee (TTM)$859,800
Tangible BV / Share (Quarterly)$1.11
P/S Ratio (Annual)19.44x
Asset Turnover (Annual)0.27x
52-Week High$2.53
Operating Margin (5Y Avg)-28966.14%
EPS Excl Extra (Annual)$-0.14
CapEx CAGR (5Y)59.46%
Tangible BV CAGR (5Y)-7.47%
26-Week Price Return65.15%
Quick Ratio (Annual)4.73x
13-Week Price Return45.33%
Total Debt / Equity (Annual)0.50x
Current Ratio (Quarterly)18.79x
Enterprise Value$979.94M
Revenue / Share Growth (5Y)-8.73%
Asset Turnover (TTM)0.31x
Book Value / Share Growth (5Y)-23.17%
Revenue / Employee (Annual)$614,900
Inventory Turnover (Annual)1.07x
Pretax Margin (Annual)-101.08%
Cash / Share (Annual)$0.26
3-Month Return Std Dev72.83%
Gross Margin (5Y Avg)98.08%
Net Income / Employee (TTM)$-322,100
ROE (Last FY)-46.81%
Net Interest Coverage (Annual)-2.22x
EPS Basic Excl Extra (Annual)$-0.14
P/FCF (TTM)56.99x
Receivables Turnover (TTM)2.35x
Total Debt / Equity (Quarterly)0.24x
EPS Incl Extra (TTM)$-0.07
Receivables Turnover (Annual)17.01x
ROI (TTM)-13.44%
P/S Ratio (TTM)13.90x
Pretax Margin (5Y Avg)-29324.68%
Revenue / Share (Annual)$0.14
Tangible BV / Share (Annual)$1.11
Price vs S&P 500 (52W)202.20%
Year-to-Date Return89.57%
5-Day Price Return0.93%
EPS Normalized (Annual)$-0.14
ROA (5Y Avg)-57.63%
Net Profit Margin (Annual)-101.08%
Month-to-Date Return35.40%
Cash Flow / Share (TTM)$-0.76
EBITD / Share (Annual)$-0.13
Operating Margin (Annual)-98.21%
LT Debt / Equity (Annual)0.46x
ROI (5Y Avg)-68.66%
LT Debt / Equity (Quarterly)0.24x
EPS Basic Excl Extra (TTM)$-0.07
P/TBV (Quarterly)3.09x
P/B Ratio (Annual)3.89x
Inventory Turnover (TTM)1.48x
Pretax Margin (TTM)-37.46%
Book Value / Share (Annual)$0.30
Price vs S&P 500 (13W)35.59%
Beta1.06x
P/FCF (Annual)8.52x
Revenue / Share (TTM)$0.17
ROE (TTM)-18.64%
52-Week Low$0.61
vGradeD
gGradeA
mGradeA
vgmGradeB
Show chart for
Earnings Surprise History
Q1 260.00est. -0.04
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.00
4.00
4.00
4.00
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
LXRXLexicon Pharmaceuticals, Inc. | D | A | A | $2.07 |
| LLYEli Lilly & Co. | D | B | B | $1082.20 |
| JNJJohnson & Johnson | C | C | C | $223.51 |
| ABBVABBVIE INC. | D | C | C | $212.93 |
| MRKMerck & Co., Inc. | C | C | C | $115.17 |
| NVSNovartis AG | C | C | C | $145.68 |
| AZNAstraZeneca PLC | D | B | C | $179.71 |
| NVONovo-Nordisk A/S | B | B | C | $44.07 |
| ABTAbbott Laboratories | C | C | D | $87.78 |
| PFEPfizer Inc. | B | C | C | $25.63 |
| TEVATeva Pharmaceutical Industries Limited American Depositary Shares | C | C | C | $34.64 |
About
Lexicon Pharmaceuticals is a biopharmaceutical company engaged in the discovery and development of small-molecule therapeutics. Its pipeline includes LX9211 and LX9851, oral drug candidates, with LX9851 targeting obesity and associated cardiometabolic disorders. The company focuses on commercializing treatments for significant unmet medical needs.